Abstract
The Southwest Oncology Group conducted a Phase II study of amonafide in patients with metastatic or recurrent squamous cell cervical cancer. Twelve of the 15 patients were fully evaluable for response and toxicity. There were no clinical responses seen; 2 patients had stable disease while 13 had progressive disease. The major complication of this therapy was myelosuppression. Four patients had life-threatening granulocytopenia (<500/μl), 3 patients had life-threatening leukopenia (<1000/μl), while 2 patients had life-threatening thrombocytopenia (<25,000/μl). Amonafide has significant toxicity but appears to be an inactive drug in metastatic or recurrent squamous cell cancer of the cervix.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 41-44 |
| Number of pages | 4 |
| Journal | American Journal of Clinical Oncology: Cancer Clinical Trials |
| Volume | 15 |
| Issue number | 1 |
| DOIs | |
| State | Published - 1992 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint Dive into the research topics of 'Evaluation of amonafide in cervical cancer, phase II. A SWOG study'. Together they form a unique fingerprint.
Cite this
Malviya, V. K., Liu, P. Y., Alberts, D. S., Surwit, E. A., Craig, J. B., & Hannigan, E. V. (1992). Evaluation of amonafide in cervical cancer, phase II. A SWOG study. American Journal of Clinical Oncology: Cancer Clinical Trials, 15(1), 41-44. https://doi.org/10.1097/00000421-199202000-00009